MK-677 Mechanism of Action

A Non-Peptide Ghrelin Receptor Agonist

MECHANISM OF ACTION

MK-677 (Ibutamoren) is a small-molecule, orally bioavailable agonist at the ghrelin receptor (GHSR-1a) — the same receptor targeted by injectable GHRPs like Ipamorelin and GHRP-6. Unlike those peptides, MK-677 is not a peptide at all; it is a synthetic spiroindoline-based compound designed specifically to survive oral administration and first-pass metabolism intact. Binding GHSR-1a on pituitary somatotrophs triggers growth hormone release through the same downstream calcium-signaling cascade as endogenous ghrelin, while also acting centrally in the hypothalamus.

Sustained, Non-Pulsatile GH Elevation

Where injectable secretagogues produce a single, discrete GH pulse per dose, MK-677's long half-life (~24 hours) means a single oral dose keeps the ghrelin receptor engaged continuously, producing a sustained elevation in both the amplitude and number of natural GH pulses across the full 24-hour cycle rather than one isolated spike. This distinguishes its pharmacokinetics from short-acting GHRPs and is the basis for once-daily oral dosing.

Downstream IGF-1 and Appetite Signaling

Growth hormone released via GHSR-1a activation drives hepatic IGF-1 production, the standard biomarker used to confirm response. Because the ghrelin receptor also mediates appetite and gastric motility in the hypothalamic arcuate nucleus, MK-677 reliably increases hunger — a mechanistic side effect shared with ghrelin itself, and one of the clearest ways MK-677's action differs in practice from the more selective injectable secretagogues like Ipamorelin.